Market Place
Sourcing Support
Aurobindo`s Generic Rufinamide Receives Approval in the U.S.
16 Jun 2023 //
FDA
Eisai Satisfies All-Case Study Requirement For Antiepileptic Agent Inovelon
02 Nov 2022 //
EISAI
Aurobindo`s Generic Rufinamide Receives Approval in the U.S.
26 Oct 2022 //
FDA
Lupin receives US FDA approval for Rufinamide tablets
18 Aug 2022 //
EXPRESS PHARMA
Lupin`s Generic Rufinamide Receives Approval in the U.S.
17 Aug 2022 //
FDA
Lupin`s Generic Rufinamide Receives Approval In US
29 Dec 2020 //
FDA
Lupin receives US FDA approval for generic Banzel
22 Dec 2020 //
PHARMABIZ
Hikma`s Generic Rufinamide Receives Approval In US
25 Apr 2019 //
FDA
Bionpharma`s Generic Rufinamide Receives Approval in US
25 Apr 2019 //
FDA
West-Ward Pharms`s Generic Rufinamide Receives Tentative Approval in US
15 Jan 2019 //
FDA
Prescription med: registration of new chemical entities in Australia
09 Jul 2018 //
TGA
Banzel®(Rufinamide): Eisai Co v. Bionpharma
24 Apr 2018 //
PATENT LITIGATION
Glenmark`s Generic Rufinamide approved in US as an anticonvulsant medication
16 May 2016 //
FDA
Roxane`s Generic Rufinamide approved in US as an anticonvulsant medication
16 May 2016 //
FDA
Presented new data, the use of Zebinix to treat partial onset seizure at AES
09 Dec 2015 //
PR NEWS WIRE
Zebinix® (eslicarbazepine acetate) in the treatment of partial seizures
07 Dec 2015 //
PR NEWS WIRE
Eisai and Glenmark Reach Settlement over Generic Version of BANZEL® (rufinamide)
30 Apr 2015 //
EISAI
Report Card: FDA Earns a Solid
25 Jan 2015 //
FDA LAW BLOG
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.